Bayer’s Glyphosate Pivot: How a Supreme Court Ruling and a New US Subsidiary Recast the Investment Case

Supreme Court preempts state cancer claims; Bayer spins off US glyphosate business into Ruveon. Stock doubles in year but RSI 85 signals caution.

A 7-2 decision by the US Supreme Court on June 25, 2026, has fundamentally recalibrated the legal landscape for Bayer’s glyphosate exposures. By ruling that federal law preempts state-level claims over missing cancer warnings, the justices effectively neutered thousands of pending lawsuits. Investors responded with a nearly 40% year-to-date surge — but the rally’s roots run deeper than a single judicial victory. The stock closed Thursday at €53.08, just a hair below its 52-week high of €53.38, after the highest court’s opinion landed days earlier.

Bayer wasted no time building on that legal momentum. On July 1, it spun off its entire US glyphosate business into a separate subsidiary, Ruveon LLC, headquartered in St. Louis and led by CEO Alfonso Alba Ordóñez. Although Ruveon remains within the Bayer group, it now operates autonomously on pricing, production, and sales. The structure looks like a dry run for a partial IPO or full divestiture, and management has signaled that cost cuts of 5% to 8% at the unit are on the table. Ruveon already commands 60% of US glyphosate production, giving it considerable leverage in the domestic market.

The price action tells its own story. Over the past 12 months, Bayer’s equity has more than doubled — a 103.57% gain that lifts the market capitalization to €47.56 billion. The run-up has been particularly explosive in recent weeks: a 53.86% advance in 30 days and another 13.88% in the last seven sessions. Anyone who bought at the August 2025 trough of €25.09 now sits on a 111.52% profit. Yet the technical picture is flashing warning lights. The relative strength index has climbed to 85.1, deep in overbought territory, and the stock trades 37.52% above its 50-day moving average — a gap that rarely persists without a pullback. Annualized volatility of 63.24% underscores how far this is from a steady climb.

Beyond the courtroom and the balance-sheet restructuring, Bayer is taking offensive steps. The company has filed an antidumping petition targeting Chinese glyphosate exporters, a move that aligns with the broader push to make Ruveon a competitive standalone player rather than a mere litigation sink. Deutsche Bank responded by raising its price target to €60, arguing that the focus is shifting from legal contingencies to the underlying crop-science operations. CEO Bill Anderson’s five-year plan for the division now has room to breathe, with the judicial overhang significantly diminished.

The market’s bet is that Bayer has reached an inflection point — one where the glyphosate chapter can be progressively closed, and the core business can command the valuation it has long deserved. But a stock that has doubled in a year and trades with extreme momentum rarely offers a straight line upward. The near-term question is whether a 85 RSI forces a pause before the next leg. Either way, Bayer has bought itself something it hasn’t had in years: a credible path to treating Monsanto-related liabilities as a contained problem, not a perpetual drag. Whether that translates into a sustained rerating depends on how efficiently Ruveon executes and how quickly the market recalibrates its risk discount.